Egetis Therapeutics AB (publ)
EGTX
Rank in Stocks
#11899
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to... Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Share Price
$1.12
Last synced: 2026-11-12
Market Cap
$518.60M
Change (1 day)
-1.00%
Change (1 year)
64.17%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Egetis Therapeutics AB (publ) (EGTX)
Category
Healthcare
EPS for Egetis Therapeutics AB (publ) (EGTX)
EPS as of June 2026 TTM: $-0.10
According to Egetis Therapeutics AB (publ)'s latest financial reports, its current EPS (TTM) is $-0.10. At the end of 2025 the company had an EPS of $-0.10, equal to its 2024 EPS of $-0.10.
EPS history for Egetis Therapeutics AB (publ) from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.10 | 1.90% |
| 2025 | $-0.10 | -0.69% |
| 2024 | $-0.10 | -19.38% |
| 2023 | $-0.13 | 33.94% |
| 2022 | $-0.09 | 46.65% |
| 2021 | $-0.06 | -78.29% |
| 2020 | $-0.30 | 155.23% |
| 2019 | $-0.12 | -34.60% |
| 2018 | $-0.18 | -11.28% |
| 2017 | $-0.20 | 56.15% |
| 2016 | $-0.13 | -23.07% |
| 2015 | $-0.17 | -19.53% |
| 2014 | $-0.21 | 44.37% |
| 2013 | $-0.14 | -25.03% |
| 2012 | $-0.19 | -12.49% |
| 2011 | $-0.22 | -85.85% |
| 2010 | $-1.54 | 162.18% |
| 2009 | $-0.59 | 164.50% |
| 2008 | $-0.22 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -15,468.01% |
US
|
|
| $-7.07 | 6,838.17% |
US
|
|
| $-5.29 | 5,091.36% |
AU
|
|
| $12.88 | -12,739.94% |
BE
|
|
| $21.56 | -21,258.00% |
NL
|
Questions about Egetis Therapeutics AB (publ)'s earnings per share (EPS)
What is Egetis Therapeutics AB (publ)'s earnings per share (EPS)?
Egetis Therapeutics AB (publ)'s earnings per share (EPS) over the last twelve months is $-0.10, as of Jun 2026.
What was Egetis Therapeutics AB (publ)'s earnings per share (EPS) in 2025?
In 2025, Egetis Therapeutics AB (publ)'s earnings per share (EPS) was $-0.10, compared with $-0.10 in 2024.
How has Egetis Therapeutics AB (publ)'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Egetis Therapeutics AB (publ)'s earnings per share (EPS) was highest in 2021 ($-0.06) and lowest in 2020 ($-0.30).
How does Egetis Therapeutics AB (publ)'s earnings per share (EPS) compare with similar companies?
Egetis Therapeutics AB (publ)'s earnings per share (EPS) ($-0.10) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.